Xue C, Xu Y, Ye W, et al. - Researchers investigated the expression of programmed death ligand-1 (PD-L1) as well as its link with prognosis, by analyzing ovarian cancer samples. They also investigated the impact and potential mechanism of a PARP inhibitor combined with PD-L1 monoclonal antibody for the management of ovarian cancer. They identified a link between PD-L1 expression in ovarian cancer tissues and the FIGO stage. The high PD-L1 expression group vs the low expression group experienced significantly lower OS. Independent risk factors that influenced the survival and prognosis of ovarian cancer patients included PD-L1 high expression and FIGO stage. Findings revealed the possible upregulation of PD-L1 expression induced by PARP inhibitors via promoting phosphorylation of chk1. The inhibitory influence of PARP inhibitors on CD8⁺T cells could be reversed by antagonistic PD-L1, which was also shown to have synergistic antitumor effect with PARP inhibitors.